Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on January 17, 2013. The filing announces the pricing of a private offering of convertible senior notes.
Key Financial Metrics and Capital Structure
- Offering Size: $110 million aggregate principal amount of convertible senior notes due 2019.
- Interest Rate: 3.25% per year, payable semiannually in arrears.
- Maturity Date: February 1, 2019.
- Conversion Terms: Initial conversion rate of 40.2945 shares per $1,000 principal amount (approx. $24.82 per share).
- Conversion Premium: Approximately 32.50% premium to the closing sale price of $18.73 on January 16, 2012.
- Over-Allotment Option: Initial purchasers have a 30-day option to purchase up to an additional $10 million in notes.
- Estimated Net Proceeds: Approximately $105.7 million (or $115.3 million if the option is fully exercised), after discounts and expenses.
Material Changes and Use of Proceeds
The Company expects to use the net proceeds as follows:
- Approximately $30.0 million to repay all amounts outstanding under and terminate its senior secured credit facility.
- The remainder to fund the continued commercialization of EXPAREL, development of additional indications for EXPAREL, and general corporate purposes.
The sale of the notes was expected to close on January 23, 2012 (noted as 2012 in the text, likely a typo for 2013 given the filing date), subject to customary closing conditions.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the completion of the offering and the use of proceeds. The Company disclaims any obligation to update these statements. Risks include the uncertainty of consummating the offering, general economic conditions, and industry-specific factors. Additional risk factors are referenced in the Company's most recent Form 10-K and a prior Form 8-K dated January 15, 2013.
Investor Verification Checklist
- Verify the actual closing date of the offering, as the text cites January 23, 2012, which conflicts with the 2013 filing date.
- Confirm whether the initial purchasers exercised the $10 million over-allotment option.
- Review the termination agreement for the senior secured credit facility to confirm the $30.0 million repayment.
- Check subsequent filings for updates on the commercialization progress of EXPAREL funded by these proceeds.